This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, G.-H. Articles by Osanai, M. Search for Related Content PubMed PubMed Citation Articles by Lee, G.-H. Articles by Osanai, M.

Mechanism of the Paradoxical, Inhibitory Effect of Phenobarbital on Hepatocarcinogenesis Initiated in Infant B6C3F₁ Mice with Diethylnitrosamine¹

Departments of Pathology [G-H. L.], Neurosurgery [T. O.], and Surgery [M. O.], Asahikawa Medical College, Asahikawa 078, Japan

Phenobarbital (PB), a classical rodent hepatopromoter, remarkably enhances hepatocarcinogenesis initiated by diethylnitrosamine (DEN) in adult B6C3F₁ mice. However, it is also known to strongly inhibit liver tumor development in the B6C3F₁ mice initiated with DEN in their infancy. The present study aimed to elucidate the unknown biological mechanisms for this paradoxical, inhibitory effect of PB on B6C3F₁ mouse hepatocarcinogenesis. Male 12-day-old infant B6C3F₁ mice were injected i.p. with DEN and, at 6 weeks of age, divided into PB-treated (PB+ group) and untreated (PB- group) animals. At 24 weeks, PB treatment was ceased for half of the PB+ animals (PB+/- group) and started for half of the PB- animals (PB-/+ group). Finally, all mice were sacrificed at 36 weeks and examined for the development of liver tumors. The mean multiplicity of gross tumors in the PB+ group was only one-fifteenth of that for the PB- group. PB-/+ animals developed fewer than half of the tumors found in PB- mice, indicating that the PB effect depends solely on the treatment duration, rather than the animal age. The effect was proven to be reversible, because the mean tumor multiplicity for the PB+/- group was seven times larger than that for the PB+ group. Stereological analysis revealed the mean volume of hepatocellular proliferative lesions in the PB- animals to be 7.7- and 4.1-fold the values for the PB+ and PB-/+ groups, respectively. The mean proliferating cell nuclear antigenlabeling indices for hepatocellular adenomas in PB+ and PB-/+ animals were also one-third of that for tumors in PB- animals, whereas no significant differences were observed with regard to the mean apoptotic index. In conclusion, the inhibitory effect of PB seemed to be primarily caused by the suppression of tumor cell proliferation. Irrespective of the group, most lesions observed were basophilic hepatocellular adenomas or foci, positive for Bcl-2 oncoprotein. They were thus distinct from the eosinophilic Bcl-2- lesions that predominate with PB promotion after the initiation of adult B6C3F₁ mice. This age-dependent nature of initiation, together with the differential responses of Bcl-2+ and Bcl-2- lesions, may be responsible for the apparently contradictory outcomes of PB treatment in infant and adult B6C3F₁ mice.

¹ Supported in part by grants from the Ministry of Education, Science, Sports and Culture; the Ministry of Health and Welfare; and the Akiyama Memorial Foundation, Japan.

² To whom requests for reprints should be addressed, at the Department of Pathology, Asahikawa Medical College, 4-5-3-11 Nishikagura, Asahikawa 078, Japan. Fax: 0166-65-8669.

Received 11/ 4/97. Accepted 2/18/98.

This article has been cited by other articles:

				S. Loeppen, C. Koehle, A. Buchmann, and M. Schwarz A {beta}-catenin-dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors Carcinogenesis, January 1, 2005; 26(1): 239 - 248. [Abstract] [Full Text] [PDF]

				Y. Yamamoto, R. Moore, T. L. Goldsworthy, M. Negishi, and R. R. Maronpot The Orphan Nuclear Receptor Constitutive Active/Androstane Receptor Is Essential for Liver Tumor Promotion by Phenobarbital in Mice Cancer Res., October 15, 2004; 64(20): 7197 - 7200. [Abstract] [Full Text] [PDF]

				S. Loeppen, D. Schneider, F. Gaunitz, R. Gebhardt, R. Kurek, A. Buchmann, and M. Schwarz Overexpression of Glutamine Synthetase Is Associated with {beta}-Catenin-Mutations in Mouse Liver Tumors during Promotion of Hepatocarcinogenesis by Phenobarbital Cancer Res., October 15, 2002; 62(20): 5685 - 5688. [Abstract] [Full Text] [PDF]

				O. Moennikes, A. Buchmann, A. Romualdi, T. Ott, J. Werringloer, K. Willecke, and M. Schwarz Lack of Phenobarbital-mediated Promotion of Hepatocarcinogenesis in Connexin32-Null Mice Cancer Res., September 1, 2000; 60(18): 5087 - 5091. [Abstract] [Full Text]

				G.-H. Lee Review Article: Paradoxical Effects of Phenobarbital on Mouse Hepatocarcinogenesis Toxicol Pathol, March 1, 2000; 28(2): 215 - 225. [Abstract] [PDF]

				J. G. Christensen, E. H. Romach, L. N. Healy, A. J. Gonzales, S. P. Anderson, D. E. Malarkey, J. C. Corton, T. R. Fox, R. C. Cattley, and T. L. Goldsworthy Altered bcl-2 family expression during non-genotoxic hepatocarcinogenesis in mice Carcinogenesis, August 1, 1999; 20(8): 1583 - 1590. [Abstract] [Full Text] [PDF]